sorafenib has been researched along with Retinal Neovascularization in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbate, I; Apicella, I; Bucolo, C; D'Agata, V; De Falco, S; Giuliano, F; La Rosa, LR; Maugeri, G; Mazzone, MG; Platania, CBM; Santonocito, M; Solfato, E; Tarallo, V; Viola, S; Zappulla, C | 1 |
| Eibl, KH; Haritoglou, C; Kampik, A; Kernt, M; Lackerbauer, CA; Liegl, RG; Neubauer, AS; Rueping, J; Ulbig, MW | 1 |
2 other study(ies) available for sorafenib and Retinal Neovascularization
| Article | Year |
|---|---|
Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye.
Topics: Administration, Ophthalmic; Animals; Choroidal Neovascularization; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Emulsions; Female; Male; Mice; Mice, Inbred C57BL; Nanostructures; Protein Kinase Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Retinal Diseases; Retinal Neovascularization; Sorafenib | 2021 |
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Topics: Adult; Aged; Astrocytes; Benzenesulfonates; Cell Survival; Humans; Light; Middle Aged; Niacinamide; Optic Disk; Phenylurea Compounds; Placenta Growth Factor; Platelet-Derived Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyridines; Retina; Retinal Neovascularization; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |